Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

ABSTRACT: Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, once weekly bortezomib, and 40 mg dexamethasone (XVd) demonstrated a significantly longer median progression-free survival (PFS), higher response rates, deeper responses, a trend to improved survival, and reduced incidence and severity of bortezomib-induced peripheral neuropathy when compared with standard twice weekly bortezomib and 80 mg dexamethasone (Vd). The pre-specified analyses described here evaluated the influence of the number of prior lines of therapy, prior treatment with lenalidomide, prior p

SUBMITTER: Mateos MV 

PROVIDER: S-EPMC8045319 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature